Dr. Eva Feldman to headline fall Health Science Lecture
Dr. Eva Feldman will headline the fall Health Science Lecture on Wednesday, Oct. 2, with an update on her landmark trial of a stem cell therapy for ALS. The trial, in which patients receive the surgical implantation of stem cells directly to their spinal cords, is expected to move into Phase 2 this fall in Ann Arbor.
The lecture takes place from 6-7 p.m. in the Kahn Auditorium of the A. Alfred Taubman Biomedical Science Research Building on the University of Michigan campus. It is open to the general public; no registration is required. Click here for directions.
The Health Science Lecture Series is sponsored by the Taubman Institute, the Program for Biology and a number of student organizations. The lectures will be held quarterly on the U-M campus and will focus on a wide variety of topico including medical research, public health, bioethics, evolutionary biology, epidemiology and many others.
Sentiment: Strong Buy
Public awareness is very important.
Most of investors out there did not know any thing about Neuralstem or CUR or Ted Harada recover from ALS. I would say his ALS is recover 90% 1 year ago. I hope he will live a normal life without using the cane or wheel chair.
Good luck to you Ted!
Sentiment: Strong Buy
I am long, long, very long, CUR. But, posters need to stop getting excited by presentations. Almost nothing new is revealed. If there's a Powerpoint with the presentation, we comb through it and find a minor update. News will come in the form of a press release, preferably 30 minutes before market opening, an SEC filing, a major partner announcement, but not, IMHO, at a presentation. So, don't get your hopes up about these presentations. Besides, who saves earth-shattering new information for the 6-7 PM on-campus lecture? Love the good Dr., but am guessing her presentation will not provide much new data.
Based on the history - you are very likely to be right on the money. Dr. Felman (IMHO) will be very postive about how things are going - but also very factual and realistic. There will NOT be a huge announcement at this time and place.
I think that the update about Phase II will be more of a recap about the dosing protocol; the more rapid pace between surgeries; and an update on the first one or two patients dosed so far. Again in my opinion, there is a slim possibility that she will say anything about how patient #1 (P2) is doing post surgery.
Folks - stop expecting so much so soon. This will happen. It IS happening, but this is a long steady battle. CUR is doing incredible things, but if you want to make money - big money - I suggest buying more and more dips and holding on long term.
The investors with the big wallets have never sold a share!
From the taubmaninstitute dot org site it does call out that she will provide an update on Phase II tomorrow.
“ALS is a disease that kills most of its victims within three to five years of diagnosis, so to have patients stabilize for years is incredibly encouraging,” said Dr. Feldman, whose research has been cited in national and international scientific publications and general media. She will present details about the Phase 1 findings, and an update on the Phase 2 round of surgeries that is taking place this fall at U-M, during the Health Science Lecture. A question-and-answer session will follow.
Date: Oct. 2, 2013
Time: 6-7 p.m.
Topic: “A stem cell trial for ALS”